Literature DB >> 23714709

Validating the Penn Acoustic Neuroma Quality Of Life Scale in a sample of Dutch patients recently diagnosed with vestibular schwannoma.

Bibian M van Leeuwen1, Jasmijn M Herruer, Hein Putter, Jeroen C Jansen, Andel G L van der Mey, Adrian A Kaptein.   

Abstract

OBJECTIVE: To examine the validity of the Penn Acoustic Neuroma Quality-of-Life Scale (PANQOL) in a sample of Dutch patients recently diagnosed with vestibular schwannoma. STUDY DESIGN AND
SETTING: Cross-sectional study in a university tertiary referral center.
METHODS: Between April 2011 and March 2012 consecutive patients (mean age, 56.4; range, 17-85 yr) diagnosed with vestibular schwannoma (n = 155) were included. The PANQOL was translated into Dutch according to the accepted rules of forward-backward translation. Quality of life at diagnosis was measured with the generic SF-36 and the disease-specific PANQOL. Factor analysis was used to explore the factor structure of the PANQOL. The scores of the patients in the current study were compared with those of patients from the United States of America. Correlations between SF-36 and PANQOL were examined to study psychometric characteristics of the PANQOL.
RESULTS: One hundred nineteen patients (76.8%) completed the questionnaires. SF-36 scores are comparable to previously published studies measuring Quality of Life at diagnosis. Factor analysis on our data has confirmed the original 7-dimensional structure of the PANQOL. The PANQOL scores from the Dutch and the USA patients are comparable. Correlations between PANQOL and SF-36 dimensions corroborate the validity of the Dutch PANQOL version.
CONCLUSION: Vestibular schwannoma patients experience a reduced quality of life immediately after the diagnostic process. The PANQOL seems to be a valid disease-specific measure of quality of life in Dutch patients who have recently been diagnosed with vestibular schwannoma.

Entities:  

Mesh:

Year:  2013        PMID: 23714709     DOI: 10.1097/MAO.0b013e31828bb2bb

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  7 in total

1.  Validation of the facial dysfunction domain of the Penn Acoustic Neuroma Quality-of-Life (PANQOL) Scale.

Authors:  Wouter L Lodder; Guleed H Adan; Chung S Chean; Tristram H Lesser; Samuel C Leong
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-08       Impact factor: 2.503

2.  The impact of acoustic neuroma on long-term quality-of-life outcomes in the United Kingdom.

Authors:  Wouter L Lodder; Bernard F A M van der Laan; Tristram H Lesser; Samuel C Leong
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-12       Impact factor: 2.503

3.  Conservative treatment of vestibular schwannoma: growth and Penn Acoustic Neuroma Quality of Life scale in French language.

Authors:  P A Oddon; M Montava; F Salburgo; M Collin; C Vercasson; J P Lavieille
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-08       Impact factor: 2.124

4.  Quality of life, social function, emotion, and facial paresis in Dutch vestibular schwannoma patients.

Authors:  Stephanie S A H Blom; Henk Aarts; Capi C Wever; Henricus P M Kunst; Gün R Semin
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-04-17

5.  What determines quality of life in patients with vestibular schwannoma?

Authors:  Ineke M J Pruijn; Wietske Kievit; Mayke A Hentschel; Jef J S Mulder; Henricus P M Kunst
Journal:  Clin Otolaryngol       Date:  2020-12-28       Impact factor: 2.597

6.  Patient-reported factors that influence the vestibular schwannoma treatment decision: a qualitative study.

Authors:  O M Neve; G Soulier; M Hendriksma; A G L van der Mey; A van Linge; P P G van Benthem; E F Hensen; A M Stiggelbout
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-07       Impact factor: 2.503

7.  The impact of vestibular schwannoma and its management on employment.

Authors:  O M Neve; J C Jansen; A G L van der Mey; R W Koot; M de Ridder; P P G van Benthem; A M Stiggelbout; E F Hensen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-04       Impact factor: 3.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.